CRH (CRH) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
2 Feb, 2026Executive summary
Achieved strong Q2 2024 results with 8% net income growth to $1.3bn, 12% Adjusted EBITDA growth to $2.3bn, and significant margin expansion, despite weather disruptions and inflationary pressures.
Raised FY24 guidance for Adjusted EBITDA to $6.82–$7.02bn, net income to $3.7–$3.85bn, and EPS to $5.40–$5.60, reflecting positive momentum and recent acquisitions.
$3.7bn invested in M&A year-to-date, including a majority stake in Adbri and major U.S. and European deals.
Ongoing share buybacks ($0.9bn YTD) and a 5% increase in the quarterly dividend to $0.35 per share, with a new $0.3bn tranche announced.
Continued focus on integrated solutions, portfolio management, and disciplined capital allocation to drive shareholder value.
Financial highlights
Q2 2024 revenues were $9.7bn, down 1% year-over-year; H1 2024 revenues reached $16.2bn (flat YoY).
Q2 Adjusted EBITDA reached $2.3bn, up 12% year-over-year, with margin expanding by 270bps to 23.4%.
Q2 EPS increased 16% to $1.89; H1 EPS was $2.05 (+31% YoY).
Organic EBITDA growth was 11% like-for-like, with acquisitions contributing an additional $15m.
Net debt at end of June was $10.3bn, with a net debt to Adjusted EBITDA ratio of 1.6x.
Outlook and guidance
Full-year 2024 Adjusted EBITDA expected between $6.82–$7.02bn; net income $3.7–$3.85bn; EPS $5.40–$5.60; capital expenditure guidance $2.2bn–$2.4bn.
Positive demand outlook in infrastructure and non-residential segments; residential new build remains subdued but long-term fundamentals are strong.
Pricing momentum expected to continue, supported by disciplined commercial management.
Latest events from CRH
- Record financials, capital structure simplification, and key governance proposals for 2026 AGM.CRH
Proxy Filing13 Mar 2026 - Delisting and preference share cancellations aim to simplify capital structure and cut costs.CRH
Proxy Filing13 Mar 2026 - Record 2025 financials, double-digit EBITDA growth, and strong 2026 outlook on infrastructure demand.CRH
Q4 202519 Feb 2026 - Q3 saw strong sales, margin gains, and M&A, with a positive outlook reaffirmed.CRH
Q3 2024 TU16 Jan 2026 - Double-digit profit growth and margin expansion achieved, with strong 2025 outlook.CRH
H2 20247 Jan 2026 - Record Q3, raised FY25 EBITDA guidance, and strong outlook driven by demand and acquisitions.CRH
Q3 2025 TU21 Dec 2025 - Record financials, new equity plan, governance updates, and strong ESG progress headline the proxy.CRH
Proxy Filing2 Dec 2025 - Record results, NYSE transition, new CEO, and 12 key AGM proposals mark a transformative year.CRH
Proxy Filing2 Dec 2025 - Definitive additional proxy materials filed for upcoming shareholder meeting.CRH
Proxy Filing2 Dec 2025